Prodapt Wins the Prestigious Salesforce Partner Innovation Award 2022
22.11.2022 15:00:00 EET | Business Wire | Press release
Prodapt, a leading global consulting, technology & managed services provider with a singular focus on the Connectedness industry, has been named a recipient of the Salesforce Partner Innovation Award in the "Communications" category. The prestigious award recognizes Prodapt’s contributions to Salesforce-driven digital transformation programs and the development of specific solution accelerators for the communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005351/en/
Prodapt is the winner of the Salesforce Partner Innovation Award 2022 in the Communications category (Graphic: Business Wire)
Each year, the Salesforce Partner Innovation Awards recognize the significant contributions Salesforce partners have made across clouds, industries, and the broader partner program – including consulting firms, digital agencies, resellers, and ISV partners. IDC, a global provider of market intelligence and advisory services for the IT, telecommunications, and consumer technology markets, facilitated and judged the nominations.
Prodapt tendered its nomination for the CRM transformation of Fiber Network Delivery to support multiple new operating models. The award affirms Prodapt’s continuous efforts in delivering value to its global clients by accelerating its transformation initiatives.
“In today’s world of fierce competition, customer volatility, and economic uncertainty, excellence in innovation has become a critical differentiator. The Partner Innovation Award in the Communications space signifies our track record in facilitating end-to-end CRM transformations that deliver business outcomes, leveraging our deep industry expertise.” – Smita Katariya | Vice President, Prodapt.
“Salesforce Partner Innovation Award winners, such as Prodapt, help customers grow faster and reach further in this new digital economy,” said Tyler Prince, Executive Vice President, Alliances & Channels at Salesforce. “Salesforce partners are integral to enabling digital transformation and driving customer success.”
For further details on Salesforce Partner Innovation Awards, visit: https://www.salesforce.com/news/stories/salesforce-2022-partner-innovation-award-winners/
Salesforce and others are among the trademarks of Salesforce.com, Inc.
About Prodapt
Prodapt is the largest and fastest-growing EXCLUSIVE player in the Connectedness space, serving global firms that ultimately seek to connect people.
Prodapt prides itself on long-tenured client relationships and has always been considered a valuable partner by clients. Prodapt serves global leaders across telecom, internet, media, and entertainment, such as Google, Facebook, Amazon, Microsoft, AT&T, Verizon, Liberty Latin America, Lumen, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, KPN, BT, and Deutsche Telekom, among many others.
Prodapt is A Great Place to Work certified company with a workforce of over 5000 spread across 32 countries spanning the Americas, Europe, Africa, and Asia. Prodapt is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005351/en/
Contact information
Manian Sivaramakrishnan
Head – Enterprise Marketing
maniannagasubra.s@prodapt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom